Prognostic impact of rapid reduction of involved free light chains in multiple myeloma patients under first-line treatment with Bendamustine, Prednisone, and Bortezomib (BPV) was written by Holzhey, Tanja;Poenisch, Wolfram;Wang, Song-Yau;Holzvogt, Madlen;Holzvogt, Bruno;Andrea, Marc;Zehrfeld, Thomas;Hammerschmidt, Doreen;Hoffmann, Franz Albert;Becker, Cornelia;Schwarzer, Andreas;Schwarz, Maik;Schoenfelder-Fricke, Uta;Edelmann, Thomas;Braunert, Leanthe;Franke, Georg-Nikolaus;Jentzsch, Madlen;Schwind, Sebastian;Bill, Markus;Grimm, Juliane;Remane, Yvonne;Platzbecker, Uwe;Scholz, Markus. And the article was included in Journal of Cancer Research and Clinical Oncology in 2021.Electric Literature of C16H21Cl2N3O2 The following contents are mentioned in the article:
Light chain involvement is observed in almost every patient (pt) with newly diagnosed multiple myeloma (MM). Owing to a relatively short half-life, rapid reduction in the involved free light chain (iFLC) is of potential prognostic value. This retrospective anal. included 92 pts with newly diagnosed MM treated with bendamustine, prednisone, and bortezomib (BPV). After a median number of two (range 1-5) BPV cycles, the majority of pts (n = 86; 93%) responded with either sCR (n = 21), CR (n = 1), nCR (n = 25), VGPR (n = 20), or PR (n = 19). PFS and OS at 48 mo were 39% and 67%, resp. At baseline, 79 out of 92 pts (86%) had iFLC levels above the upper standard level and an abnormal ratio of involved to uninvolved free light chain 鈮?8. In a subgroup anal. of these pts, we evaluated the prognostic importance of an early reduction of the iFLC during the first two BPV cycles. A reduction 鈮?50% of the iFLC on day 8 of the first cycle was observed in 31 of 69 pts. These pts had a significantly better median PFS of 49 mo as compared to 20 mo in 38 pts with a lower iFLC reduction (p = 0.002). In contrast, OS did not differ significantly with a 48 mo survival of 77% vs 69% (p > 0.05). These results indicate that a rapid decrease in the iFLC on day 8 is an early prognostic marker for newly diagnosed MM pts undergoing BPV treatment. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Electric Literature of C16H21Cl2N3O2).
4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Imidazole is the basic core of some natural products such as histidine, purine, histamine and DNA based structures, etc. Among the different heterocyclic compounds, imidazole is better known due to its broad range of chemical and biological properties. This ring system is present in important biological building blocks, such as histidine and the related hormone histamine.Electric Literature of C16H21Cl2N3O2
Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem